The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Open accessAbstract
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases. TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and therefore do not respond to hormonal or anti‑HER2 therapies. TNBC is a particularly aggressive form of breast cancer that generally displays poorer prognosis compared to other breast cancer subtypes. TNBC is chemotherapy sensitive, and this treatment remains the standard of care despite its limited benefit. Recent advances with novel agents have been made for specific subgroups with PD‑L1+ tumors or germline Brca‑mutated tumors. However, only a fraction of these patients responds to immune checkpoint or PARP inhibitors and even those who do respond often develop resistance and relapse. Various new agents and combination strategies have been explored to further understand molecular and immunological aspects of TNBC. In this review, we discuss clinical trials in the management of TNBC as well as perspectives for potential future treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“It showed efficacy in targeting Pik3ca -mutated breast cancer (65) and was FDA approved in 2019 in combination with fulvestrant for postmenopausal women and men, with HR + , HER2-negative, Pik3ca -mutated, advanced or metastatic breast cancer following progression on or after an endo-crine-based…”
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Giuliano, A. E., Connolly, J. L., Edge, S. B., Mittendorf, E. A., Rugo, H. S., Solin, L. J., Weaver, D. L., Winchester, D. J., & Hortobagyi, G. N. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21393 · Cited by 961
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Molyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 631
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
(2017) · New England Journal of Medicine · doi:10.1056/nejmx170012 · Cited by 431
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2984 · Cited by 311
Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Plevritis, S. K., Munoz, D., Kurian, A. W., Stout, N. K., Alagoz, O., Near, A. M., Lee, S. J., van den Broek, J. J., Huang, X., Schechter, C. B., et al. (2018) · JAMA · doi:10.1001/jama.2017.19130 · Cited by 302
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andreetta, C., Mansutti, M., Pisa, F. E., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0002 · Cited by 295
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.005 · Cited by 285
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Anderberg, C., Li, H., Fredriksson, L., Andrae, J., Betsholtz, C., Li, X., Eriksson, U., & Pietras, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2724 · Cited by 249
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
An overview of precision oncology basket and umbrella trials for clinicians
Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K., & Mills, E. J. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21600 · Cited by 233
Buisseret, L., Pommey, S., Allard, B., Garaud, S., Bergeron, M., Cousineau, I., Ameye, L., Bareche, Y., Paesmans, M., Crown, J. P. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx730 · Cited by 232
Targeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 225
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
Hartman, A., Kaldate, R. R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C. A., Silberman, M. A., et al. (2012) · Cancer · doi:10.1002/cncr.26576 · Cited by 220
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216 · cited 1×
“However, dinaciclib inhibits tumor growth in combination with anti-PD-1 (82).”
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review
Kono, M., Fujii, T., Lim, B., Karuturi, M. S., Tripathy, D., & Ueno, N. T. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4975 · Cited by 215
Sharma, D., Saxena, N. K., Davidson, N. E., & Vertino, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0402 · Cited by 208
Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X.-F., Bencsath, K. P., Panageas, K. S., Chin, J., Hudis, C. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626298 · Cited by 205
Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Murthy, R. K., Damodaran, S., DeSnyder, S. M., Brewster, A. M., Barcenas, C. H., Valero, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01304 · Cited by 195
Santonja, A., Sánchez-Muñoz, A., Lluch, A., Chica-Parrado, M. R., Albanell, J., Chacón, J. I., Antolín, S., Jerez, J. M., Haba, J. D. L., de Luque, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25413 · Cited by 192
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1000 · Cited by 186
Martin, R. W., Orelli, B. J., Yamazoe, M., Minn, A. J., Takeda, S., & Bishop, D. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0290 · Cited by 177
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1729 · Cited by 162
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Liu, Y., Burness, M. L., Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M. D., Shang, L., Fox, A., Luther, T. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1348 · Cited by 162
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Dean, J. L., McClendon, A. K., & Knudsen, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365494 · Cited by 160
Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Poznak, C. H. V., Storniolo, A. M., Nangia, J. R., Ericsson, P. I. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2170 · Cited by 160
Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
Anestis, A., Zoi, I., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Molecules · doi:10.3390/molecules25020358 · Cited by 160
FOXA1 represses the molecular phenotype of basal breast cancer cells
Bernardo, G. M., Bebek, G., Ginther, C., Sizemore, S. T., Lozada, K. L., Miedler, J. D., Anderson, L. A., Godwin, A. K., Abdul‐Karim, F. W., Slamon, D., et al. (2012) · Oncogene · doi:10.1038/onc.2012.62 · Cited by 158
Roswall, P., Bocci, M., Bartoschek, M., Li, H., Kristiansen, G., Jansson, S., Lehn, S., Sjölund, J., Reid, S., Larsson, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4494 · Cited by 156
Thike, A. A., Chong, L. Y.-Z., Cheok, P. Y., Li, H. H., Yip, G. W. C., Bay, B., Tse, G. M.-K., Iqbal, J., & Tan, P. H. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.145 · Cited by 155
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Safonov, A. M., Jiang, T., Bianchini, G., Győrffy, B., Karn, T., Hatzis, C., & Pusztai, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3478 · Cited by 153
Carey, J. P. W., Karakaş, C., Bui, T. N., Chen, X., Vijayaraghavan, S., Zhao, Y., Wang, J., Mikule, K. W., Litton, J. K., Hunt, K. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1494 · Cited by 151
CD73 as a potential opportunity for cancer immunotherapy
Ghalamfarsa, G., Kazemi, M. H., Mohseni, S. R., Masjedi, A., Hojjat‐Farsangi, M., Azizi, G., Yousefi, M., & Jadidi‐Niaragh, F. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559829 · Cited by 151
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 125
Echavarría, I., López‐Tarruella, S., Picornell, A. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1912 · Cited by 120
Yam, C., Mani, S. A., & Moulder, S. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0095 · Cited by 117
Rad51 supports triple negative breast cancer metastasis
Wiegmans, A. P., Al‐Ejeh, F., Chee, N., Yap, P.-Y., Gorski, J. J., Silva, L. M. D., Bolderson, E., Chenevix‐Trench, G., Anderson, R. L., Simpson, P. T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1923 · Cited by 111
Nie, L., Wei, Y., Zhang, F., Hsu, Y.-H. E., Chan, L.-C., Xia, W., Ke, B., Zhu, C., Deng, R., Tang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13105-5 · Cited by 111
Consideration of breast cancer subtype in targeting the androgen receptor
Venema, C. M., Bense, R. D., Steenbruggen, T. G., Nienhuis, H. H., Qiu, S.-Q., van Kruchten, M., Brown, M. A., Tamimi, R. M., Hospers, G. A. P., Schroder, C. P., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.005 · Cited by 96
Cretella, D., Fumarola, C., Bonelli, M. A., Alfieri, R. R., Monica, S. L., Digiacomo, G., Cavazzoni, A., Galetti, M., Generali, D., & Petronini, P. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49484-4 · Cited by 88
Marzio, A., Puccini, J., Kwon, Y., Maverakis, N., Arbini, A., Sung, P., Bar‐Sagi, D., & Pagano, M. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.11.003 · Cited by 74
Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer
Su, Y., Subedee, A., Bloushtain-Qimron, N., Savova, V., Krzystanek, M., Li, L., Marusyk, A., Tabassum, D. P., Zak, A., Flacker, M. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.011 · Cited by 72
Bardia, A., Gucalp, A., DaCosta, N., Gabrail, N. Y., Danso, M. A., Ali, H. Y., Blackwell, K., Carey, L., Eisner, J. R., Baskin-Bey, E. S., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4813-z · Cited by 53
Extracellular Adenine Nucleotides Inhibit the Activation of Human CD4+ T Lymphocytes
Duhant, X., Schandené, L., Bruyns, C., Gonzalez, N. S., Goldman, M., Boeynaems, J., & Communi, D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.15 · Cited by 50
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clark, A. S., McAndrew, N. P., Troxel, A. B., Feldman, M. D., Lal, P., Rosen, M. A., Burrell, J. A., Redlinger, C., Gallagher, M., Bradbury, A. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0790 · Cited by 49
Yang, C., LaBaff, A. M., Wei, Y., Nie, L., Xia, W., Huo, L., Yamaguchi, H., Hsu, Y. H., Hsu, J. L., Liu, D., et al. (2015) · PubMed Central · Cited by 47
Hida, A. I., Watanabe, T., Sagara, Y., Kashiwaba, M., Sagara, Y., Aogi, K., Ohi, Y., & Tanimoto, A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05390-x · Cited by 46
Pitts, T. M., Simmons, D. M., Bagby, S. M., Hartman, S. J., Yacob, B. W., Gittleman, B., Tentler, J. J., Cittelly, D. M., Ormond, D. R., Messersmith, W. A., et al. (2020) · Cancers · doi:10.3390/cancers12030719 · Cited by 28
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
Okuma, H. S., & Yonemori, K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_13 · Cited by 25
Modi, S., Ohtani, S., Lee, C. C., Wang, K., Saxena, K., & Cameron, D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps1102 · Cited by 19
MYC impairs resolution of site-specific DNA double-strand breaks repair
Ambrosio, S., Amente, S., Napolitano, G., Palo, G. D., Lania, L., & Majello, B. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.02.005 · Cited by 12
Mitri, Z. I., Vuky, J., Kemmer, K. A., Savin, M. A., Parmar, S. S., Kolodzie, A., Johnson, B., Williams-Belizaire, R., Gray, J. W., & Mills, G. B. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps1111 · Cited by 8
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Montazersaheb, S., Farahzadi, R., Mansouri, E., Jafari, S., & Fathi, E. (2026) · Scientific Reports · doi:10.1038/s41598-026-35662-8 · Cited by 5
Metadata
- Authors
- Won, K., & Spruck, C.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2020-10-16
- Volume
- 57
- Issue
- 6
- Pages
- 1245-1261
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W3093085805
- Cited by
- 527
- References
- 100
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.